Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma
Jazyk angličtina Země Řecko Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25275055
PII: 34/10/5555
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarkers, endometrial carcinoma, tumor-associated macrophages, tumor-infiltrating lymphocytes,
- MeSH
- antigeny CD3 metabolismus MeSH
- leukocyty imunologie patologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory endometria imunologie mortalita patologie chirurgie MeSH
- počet buněk MeSH
- prognóza MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- stupeň nádoru MeSH
- tumor infiltrující lymfocyty imunologie metabolismus MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- antigeny CD3 MeSH
AIM: The aim of the present study was to investigate tumor-infiltrating leukocytes in patients with endometrial carcinoma. PATIENTS AND METHODS: Cluster of differentiation (CD)3(+), CD8(+) and C20(+) tumor-infiltrating lymphocytes (TILs) and CD68(+) tumor-associated macrophages (TAMs) were evaluated retrospectively by immunohistochemistry in tumor specimen from 124 patients with endometrial carcinoma. RESULTS: A significant decrease of CD3(+) TILs and an increase of CD68(+) TAM count was associated with higher tumor stage. In patients with early-stage, high-risk tumors, low intraepithelial CD3(+) TIL counts were associated with significantly inferior survival. In multivariate analysis of patients with early-stage tumors, intraepithelial CD3(+) TIL counts were an independent predictor of survival. CONCLUSION: In patients with endometrial carcinoma a decrease of intraepithelial CD3(+) TIL counts is associated with advanced stage and high risk group. Intraepithelial CD3(+) TIL counts are an independent predictor of survival in patients with early tumors.
Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study
Neopterin as a biomarker of immune response in cancer patients
